Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06271538

Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome

A Randomized Double-Blind Placebo-controlled Clinical Trial on the Efficacy of Skål Pro (Lactobacillus Plantarum 299 and Galacto-oligosaccharides) in Improving Severity of Symptoms, Stool Forms, Quality of Life and Psychological Dysfunction in Patients With Irritable Bowel Syndrome (IBS)

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
EP Plus Group Sdn Bhd · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.

Detailed description

Irritable bowel syndrome (IBS) is a condition linked to disturbances in the gut-brain axis and dysbiosis. Although probiotic modulation of dysbiosis appears promising for IBS treatment, identifying the specific beneficial strains remains uncertain. Furthermore, even with an effective probiotic strain, variations in efficacy among populations are observed due to environmental heterogeneity, particularly dietary influences. This study seeks to provide efficacy insights into Skal Pro powder 2g (containing Lactobacillus plantarum 299v 1x10\^10 colony forming unit (CFU) and GOS), shedding light on the unique mechanisms of LP299V within the Malaysian population through a randomized controlled trial (RCT).

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTSkal ProOne sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10\^10 CFU and GOS
OTHERPlaceboOne sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet

Timeline

Start date
2024-10-17
Primary completion
2025-07-31
Completion
2025-11-30
First posted
2024-02-21
Last updated
2024-11-08

Locations

1 site across 1 country: Malaysia

Source: ClinicalTrials.gov record NCT06271538. Inclusion in this directory is not an endorsement.